X0508 4 2025-12-18-05:00 false 0000924515 GUIDED THERAPEUTICS INC GTHP 0001348439 Imhoff John E 5853 PEACHTREE CORNERS EAST SUITE B PEACHTREE CORNERS GA 30092 true false true false false Common Stock 2025-12-18-05:00 4 C false 195460 0.07 A 19658955 D Common Stock 2026-01-05-05:00 4 J false 25338 A 19684293 D Common Stock 2026-02-02-05:00 4 C false 312720 0.07 A 19997013 D Common Stock 2026-02-25-05:00 4 X false 500000 A 20497013 D Preferred Series E Stock 2026-02-27-05:00 4 J false 100 D 0 D Common Stock 2026-02-27-05:00 4 J false 400000 A 20897013 D Common Stock 2026-02-27-05:00 4 C false 156086 0.07 A 21053099 D Convertible Promissory Note 0.07 2025-12-18-05:00 4 C false 195460 D 2025-11-28-05:00 2027-02-28-05:00 Common Stock 195460 150000 D Convertible Promissory Note 0.07 2026-02-02-05:00 4 C false 312720 D 2026-01-30-05:00 2027-02-28-05:00 Common Stock 312720 130000 D Warrants 0.65 2026-02-25-05:00 4 J false 500000 D 2022-09-01-05:00 2026-09-01-05:00 Common Stock 500000 0 D Warrants 0.65 2026-02-25-05:00 4 J false 500000 A 2026-02-25-05:00 2027-09-01-05:00 Common Stock 500000 500000 D Warrants 0.50 2026-02-25-05:00 4 J false 500000 D 2022-09-01-05:00 2026-09-01-05:00 Common Stock 500000 0 D Warrants 0.20 2026-02-25-05:00 4 J false 500000 A 2026-02-25-05:00 2026-02-25-05:00 Common Stock 500000 500000 D Warrants 0.20 2026-02-25-05:00 4 X false 500000 D 2026-02-25-05:00 2026-02-25-05:00 Common Stock 500000 0 D Convertible Promissory Note 0.07 2026-02-27-05:00 4 C false 156086 0.07 D 2026-02-27-05:00 2027-02-28-05:00 Common Stock 156086 120000 D On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note. These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.3157. On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note. During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027. On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price. On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note. /s/ John E. Imhoff 2026-03-12-05:00